Ascendis Pharma AS (ASND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.06B
Last updated: Nov 17, 2026 at 4:23 PM ET
Ascendis Pharma AS (ASND) Stock Chart
Ascendis Pharma AS (ASND) has a latest price of $271.19 on Nov 17, 2026, 3.9% below its 52-week high of $282.15. Its price rose 32.7% over the past 12 months. The month-end price rose 1,190.5% over the 10 years through Oct 2026, a compound annual rate of 29.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $266.72 in Jun 2026 and its lowest $19.47 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ASND with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ASND.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 4.5%, and over 6 months it rose 14.0%. The month-end price rose 181.3% over the 3 years through Oct 2026, a compound annual rate of 41.2%.
| Period | Change |
|---|---|
| 1 month | +17.9% |
| 3 months | +4.5% |
| 6 months | +14.0% |
| 12 months | +32.7% |
| 12 months, with dividends | +32.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +181.3% | +41.2% |
| 5 years | +65.7% | +10.6% |
| 10 years | +1,190.5% | +29.1% |
Price by Year
Its best calendar year was 2019, when the price rose 122.1%, and its weakest was 2021, when it fell 19.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $251.27 | +17.8% |
| 2025 | $213.24 | +54.9% |
| 2024 | $137.67 | +9.3% |
| 2023 | $125.95 | +3.1% |
| 2022 | $122.13 | -9.2% |
| 2021 | $134.53 | -19.3% |
| 2020 | $166.78 | +19.9% |
| 2019 | $139.12 | +122.1% |
| 2018 | $62.65 | +56.4% |
| 2017 | $40.06 | +97.9% |
Trading Range
The price is 11.7% above its 50-day average of $242.71 and 12.8% above its 200-day average of $240.32.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $271.19 | |
| 52-week high | $282.15 | -3.9% |
| 52-week low | $188.08 | +44.2% |
| 50-day average | $242.71 | +11.7% |
| 200-day average | $240.32 | +12.8% |
Price Risk
Over 3 years, its largest fall from a peak was 29.2%.
| Measure | Value |
|---|---|
| 1-year beta | 0.44 |
| Largest fall, 1 year | -19.7% |
| Largest fall, 3 years | -29.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ASND
What is ASND's 1-year price change?
Ascendis Pharma AS's price rose 32.7% over the past 12 months. With dividends included, the 12-month total return was 32.7%.
What is ASND's 5-year price change?
Ascendis Pharma AS's month-end price rose 65.7% over the 5 years through Oct 2026, a compound annual rate of 10.6%. These figures leave out dividends.
What is ASND's 52-week high and low?
Ascendis Pharma AS's 52-week high is $282.15 and its 52-week low is $188.08. Its latest price of $271.19 on Nov 17, 2026 is 3.9% below the high.
What is ASND's beta?
Ascendis Pharma AS's 1-year beta against the S&P 500 is 0.44, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 19.7%.
Is the ASND chart free?
Yes. Advanced Charting for ASND is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ASND pages: Overview, Charting, Financials, Statistics, Valuation, Competitors